Assessing real-world effectiveness of therapies: what is the impact of incretin-based treatments on hospital use for patients with type 2 diabetes?

Clémence Bussière, Pauline Chauvin (), Jean-Michel Josselin () and Christine Sévilla-Dedieu
Additional contact information
Clémence Bussière: ERUDITE - Equipe de Recherche sur l’Utilisation des Données Individuelles en lien avec la Théorie Economique - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12 - Université Gustave Eiffel, Fondation MGEN pour la santé publique
Pauline Chauvin: LIRAES (URP_ 4470) - Laboratoire Interdisciplinaire de Recherche Appliquée en Economie de la Santé - UPCité - Université Paris Cité
Jean-Michel Josselin: CREM - Centre de recherche en économie et management - UNICAEN - Université de Caen Normandie - NU - Normandie Université - UR - Université de Rennes - CNRS - Centre National de la Recherche Scientifique
Christine Sévilla-Dedieu: LIRAES (URP_ 4470) - Laboratoire Interdisciplinaire de Recherche Appliquée en Economie de la Santé - UPCité - Université Paris Cité

Post-Print from HAL

Abstract: BACKGROUND: Managing type 2 diabetes represents a major public health concern due to its important and increasing prevalence. Our study investigates the impact of taking incretin-based medication on the risk of being hospitalized and the length of hospital stay for individuals with type 2 diabetes. METHOD: We use claim panel data from 2011 to 2015 and provide difference-in-differences (DID) estimations combined with matching techniques to better ensure the treatment and control groups' comparability. Our propensity score selects individuals according to their probability of taking an incretin-based treatment in 2013 (N = 2,116). The treatment group includes individuals benefiting from incretin-based treatments from 2013 to 2015 and is compared to individuals not benefiting from such a treatment but having a similar probability of taking it. RESULTS: After controlling for health-related and socio-economic variables, we show that benefiting from an incretin-based treatment does not significantly impact the probability of being hospitalized but does significantly decrease the annual number of days spent in the hospital by a factor rate of 0.621 compared with the length of hospital stays for patients not benefiting from such a treatment. CONCLUSION: These findings highlight the potential implications for our health care system in case of widespread use of these drugs among patients with severe diabetes.

Keywords: Diabetes; Drug assessment; Hospital use; Observational data; Quasi-experiment (search for similar items in EconPapers)
Date: 2022-10-22
Note: View the original document on HAL open archive server: https://hal.science/hal-03830798v1
References: View references in EconPapers View complete reference list from CitEc
Citations:

Published in Health Economics Review, 2022, 12 (1), pp.53. ⟨10.1186/s13561-022-00397-5⟩

Downloads: (external link)
https://hal.science/hal-03830798v1/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-03830798

DOI: 10.1186/s13561-022-00397-5

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().